Crossref
4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications
JAMA · 23.06.2026 · 335 (24) · e267399
DOI: 10.1001/jama.2026.7399 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, online erschienen am 23.06.2026.
Abstract (Originalsprache)
This study evaluated whether addition of a locking fluid containing 4% tetrasodium EDTA (t-EDTA) reduced central venous access device (CVAD) complications compared with usual care among adults in intensive care units (ICUs).
Zitieren
APA
(2026). 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA, 335(24), e267399. https://doi.org/10.1001/jama.2026.7399
Vancouver
4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA. 2026;335(24):e267399. doi:10.1001/jama.2026.7399
BibTeX
@article{euvimed2026,
title = {4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications},
journal = {JAMA},
year = {2026},
volume = {335},
number = {24},
pages = {e267399},
doi = {10.1001/jama.2026.7399}
}
EUVIMED